Intellia Therapeutics

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NTLA and other ETFs, options, and stocks.

About NTLA

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases.

CEO

John M. Leonard

CEOJohn M. Leonard

Employees

485

Employees485

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2014

Founded2014

Employees

485

Employees485

NTLA Key Statistics

Market cap

3.91B

Market cap3.91B

Price-Earnings ratio

—

Price-Earnings ratio—

Dividend yield

—

Dividend yield—

Average volume

719.15K

Average volume719.15K

High today

$50.41

High today$50.41

Low today

$48.61

Low today$48.61

Open price

$49.54

Open price$49.54

Volume

197.73K

Volume197.73K

52 Week high

$130.33

52 Week high$130.33

52 Week low

$37.08

52 Week low$37.08

Analyst ratings

86%

of 29 ratings

Buy

86.2%

Hold

10.3%

Sell

3.4%

NTLA Earnings

-$1.96

-$1.31

-$0.65

$0.00

Q1 FY21

Q2 FY21

Q3 FY21

Q4 FY21

Q1 FY22

Q2 FY22

Q3 FY22

Q4 FY22

Estimated

— per share

Estimated— per share

Actual

Expected Feb 23, Pre-Market

ActualExpected Feb 23, Pre-Market